发明名称 |
PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER |
摘要 |
The present disclosure relates to pharmaceutical combinations comprising (a) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, and (b) an epidermal growth factor receptor (EGFR) inhibitor, for the treatment or prevention of cancer. The disclosure also provides related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer. |
申请公布号 |
WO2017037576(A1) |
申请公布日期 |
2017.03.09 |
申请号 |
WO2016IB55044 |
申请日期 |
2016.08.24 |
申请人 |
NOVARTIS AG;CAPONIGRO, Giordano;HORN-SPIROHN, Thomas;LEHAR, Joseph |
发明人 |
CAPONIGRO, Giordano;HORN-SPIROHN, Thomas;LEHAR, Joseph |
分类号 |
A61K31/517;A61K31/519;A61P35/00 |
主分类号 |
A61K31/517 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|